Guidelines for the use of cannabinoid compounds in chronic pain

AJ Clark MD FRCP1, ME Lynch MD FRCP2, M Ware MBBS MRCP MSc3, P Beaulieu MD PhD FRCA4, IJ McGilveray PhD5, D Gourlay MD FRCP FASAM6

OBJECTIVE: To provide clinicians with guidelines for the use of cannabinoid compounds in the treatment of chronic pain.

METHODS: Publications indexed from 1990 to 2005 in the National Library of Medicine Index Medicus were searched through PubMed. A consensus concerning these guidelines was achieved by the authors through review and discussion.

RESULTS: There are few clinical trials, case reports or case series concerning the use of cannabinoid compounds in the treatment of chronic pain. There are no randomized clinical trials examining the use of herbal cannabis in the treatment of chronic pain.

CONCLUSIONS: A practical approach to the treatment of chronic pain with cannabinoid compounds is presented. Specific suggestions about the off-label dosing of nabilone (Cesamet, Valeant Canada Limited) and dronabinol (Marinol, Solvay Pharma Inc, Canada) in the treatment of chronic pain are provided.

Key Words: Cannabinoid; Chronic pain; Dronabinol; Guideline; Nabilone; Treatment

In Canada, there are presently two synthetic cannabinoids and one cannabis-based medicine available by prescription. The synthetic agents include nabilone (Cesamet, Valeant Canada Limited) and the synthetic delta-9-tetrahydrocannabinol dronabinol (Marinol, Solvay Pharma Inc, Canada), both of which are available in oral preparations. The cannabis-based medicine (Sativex, GW Pharma Ltd, United Kingdom) is available as a buccal spray and consists of an extract containing delta-9-tetrahydrocannabinol and cannabidiol. Sativex has only recently been approved by Health Canada (as of April 2005) under a conditional notice of compliance.

The approved indication for nabilone and dronabinol is for antiemesis in chemotherapy-induced nausea and vomiting, while the indication listed for the buccal extract is adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis. Any of these agents prescribed for pain would be considered an ‘off-label’ use.

In addition, since July 30, 2001, Canadians have had the opportunity to apply for a license to possess herbal cannabis under the Medical Marijuana Access Regulations. Patients may also apply for a license to grow marijuana or may purchase marijuana supplied by Health Canada by completing appropriate forms.

1University of Calgary, Calgary, Alberta; 2Dalhousie University, Halifax, Nova Scotia; 3McGill University; 4Université de Montréal, Montréal, Québec; 5University of Ottawa, Ottawa; 6Centre for Addiction and Mental Health, Toronto, Ontario.

Correspondence: Dr AJ Clark, Chronic Pain Centre, Calgary Health Region, #160, 2210 – 2nd Street SW, Calgary, Alberta T2S 3C3.

Telephone 403-943-9900, fax 403-209-2955, e-mail john.clark@calgaryhealthregion.ca
the buccal cannabis-based extract and, thus, these guidelines will focus on the two oral cannabinoids currently available by prescription in Canada. For information regarding herbal cannabis under the Medical Marijuana Access Regulations, clinicians are referred to the Health Canada Web site (http://www.hc-sc.gc.ca/hec-csc/ocma/).

In general, contraindications to the use of cannabinoids include pregnancy, uncontrolled hypertension, active ischemic heart disease, arrhythmias and schizophrenia. A history of psychosis is a relative contraindication, and because cannabinoids can cause anxiety, they should be used with caution in patients with a past or current anxiety or panic disorder. Moreover, cannabinoids can cause sedation and cognitive effects. Thus, the usual cautions given for opioids, benzodiazepines or any potentially sedating agent are applicable. Patients should be cautioned not to drive or to operate heavy machinery, etc, if experiencing any side effects that would impair their performance in these activities. Patients with comorbid depression and other psychiatric disorders should be carefully monitored. Cannabinoids should be administered initially at low doses and titrated slowly to balance positive and negative acute effects. Patients should be advised of the likelihood and nature of acute effects, and close monitoring is advised during initial dose titration.

EVALUATING A PATIENT FOR A TRIAL OF A CANNABINOID

Prudent medical practice incorporates a comprehensive evaluation of a patient when new therapies are considered. The following suggestions are similar to those endorsed by the Canadian Pain Society in its consensus statement and guidelines for the use of opioid analgesics in the treatment of noncancer pain (9):

- perform a history and examination;
- assess the level of pain;
- assess psychological contributors and risk of addiction or substance abuse;
- document any history or current use of illicit or nonprescribed drugs, including cannabis and synthetic cannabinoids;
- determine the effect of the previous use of cannabinoids on pain;
- consider urine drug screening to assess the current use of prescribed and nonprescribed medications;
- set goals of treatment with a cannabinoid – consider reduction of pain, increased functional abilities, improved sleep quality, increased quality of life and a reduction in the use of other medications;
- develop a treatment plan incorporating these goals;
- discuss possible side effects that may be experienced with use (eg, central nervous system, cardiovascular and respiratory);
- discuss the risks of addiction;
- develop a follow-up schedule to periodically review the patient (the five As – Analgesia, Activities, Adverse events, Abuse behaviours and Adequate documentation);
- determine whether the goals of treatment are being achieved and the appropriateness of response; and

consider developing a treatment agreement with the patient, particularly if he/she is at risk.

Documentation is essential to demonstrate the evaluation of the patient, the rationale for the use of a cannabinoid in the context of the overall management plan and the periodic review of the patient’s status.

An algorithm for the treatment of chronic pain is provided in Figure 1.

Common side effects associated with the use of the cannabinoids are detailed in Table 1.

Risk of addiction to and abuse of Cesamet, Marinol and Sativex

Marinol is available suspended in sesame oil in capsule form in 2.5 mg, 5 mg and 10 mg strengths. Cesamet is available as a pulvule (powder-containing capsule) in 0.5 mg and 1 mg strengths. Sativex is available as a buccal spray. As Gourlay (10) notes in the present supplement, it has been previously reported that the abuse liability of Marinol is low because the drug lacks the desirable qualities of rapid onset and titratability commonly seen in drugs of abuse. The same is true for Cesamet due to its compounding as a pulvule; it too does not appear to lead to misuse or abuse. Comparisons of the reinforcing properties of oral tetrahydrocannabinol, smoked cannabis and nabilone in subjects with previous cannabis experience indicate that smoked cannabis was significantly more reinforcing than all other cannabis compounds studied, regardless of
drug-use history (10). We do not currently have adequate information concerning Sativex and abuse liability.

Guidelines for the use of Cesamet

Cesamet has been available in Canada since 1981 and is indicated for use as an antiemetic and to treat anorexia associated with AIDS. There have been no adequate randomized clinical trials on the use of Cesamet in chronic pain, although there are two clinical reports (11,12) showing a modest benefit in some patients.

When other therapies have failed to provide adequate pain relief or have caused unacceptable side effects, it is reasonable to consider a trial of an oral cannabinoid:

• initiate Cesamet at 0.5 mg orally at night time; and
• increase dose by 0.5 mg every two to three days to a maximum dose of 2 mg twice daily orally.

Guidelines for the use of Marinol

Marinol is indicated for use as an antiemetic. There is one randomized clinical trial (13) of Marinol (with a dose up to 10 mg) showing a modest effect in the treatment of central pain in patients with multiple sclerosis. An ‘N-of-1’ trial in noncancer pain subjects has demonstrated improvement in pain similar to that with codeine at doses of 10 mg or higher (14).

Sativex

Sativex is only approved for use as an adjunctive treatment for the symptomatic relief of neuropathic pain in multiple sclerosis. The product monograph for Sativex recommends a “gradual increase in dose as needed and tolerated until satisfactory pain relief is achieved” (15). There is insufficient published information on the dosing of Sativex to make recommendations about its use at this time.

REFERENCES